The Effect of Phosphodiesterase-5 Inhibitor on Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis, A Single Centre Study | ||
The Medical Journal of Cairo University | ||
Volume 92, Issue 03, March 2024, Pages 129-138 PDF (159.42 K) | ||
Document Type: Original Article | ||
DOI: 10.21608/mjcu.2024.353095 | ||
Author | ||
GHADA S. MAHMOUD, M.D.**; HADEEL A. MOHAMMED, M.D.* MENNA H. MOHAMMED, M.D.* NAGLAA B. AHMED, M.D.*; AHMED A. ALHADIDY, M.D.*; HOSAM H. MASOUD, M.D.*; | ||
The Departments of Chest* and Cardiology**, Faculty of Medicine, Cairo University | ||
Abstract | ||
Abstract Background: Pulmonary hypertension (PH), group III of the international aetiological classification, is a frequent and severe complication of interstitial lung diseases (ILDs), espe-cially idiopathic pulmonary fibrosis (IPF), Phosphodiesterase 5 inhibitor (Sildenafil) appears induce vasodilatation in well-ven-tilated lung tissue. Such vasodilatation could gas exchange in patients with idiopathic pulmonary fibrosis. Aim of Study: To assess the effect of phosphodiesterase 5 inhibitors (sildenafil) on pulmonary hypertension in patient with IPF after 3 months of treatment. Patients and Methods: Fifty patients with pulmonary hy pertension secondary to idiopathic pulmonary fibrosis, divided into two groups: The first group (30 patients) received phos phodiesterase 5 inhibitors; the second group (20 patients) didn’ receive phosphodiesterase 5 inhibitors; all the patients had follow up visit after 3 months with assessment of high resolu tion CT scan & transthoracic echocardiography. Results: As regarding the class of dyspnea, there was sta tistically significant difference between the two groups with p-value (<0.001) favoring the treatment group. As regarding 6MWD and the change in PO2, there was statistically signifi cant difference with p-value (<0.001) favouring the treatmen group. Also, there was statistically significant difference p-val ue (0.001) favouring the treatment group regarding the change in FVC%. Conclusion: This study supports that the patients who re ceived sidinafil had a better outcome as regards class of dysp nea, 6 MWD, PO2, FVC% and PASP. | ||
Keywords | ||
Phosphodiesterase 5 inhibitor; Pulmonary hyper tension; Idiopathic pulmonary fibrosis | ||
Statistics Article View: 149 PDF Download: 215 |